908 Devices

908 Devices

MASS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +138.6% in FY2025

Kevin J. Knopp, Ph.D. is the CEO of 908 Devices and was paid $1.6M in FY2025 (Dec), down 22%.

Pay$100 in the stock at the end of FY21 → $20
CEO pay is from each 908 Devices proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Kevin J. Knopp, Ph.D.FY2025
  2. 2Mark S. LevineFY2025
  3. 3Joseph H. Griffith IVFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

908 Devices paid its 3 named executives $4.0M in total in FY2025 (Dec). CEO Kevin J. Knopp, Ph.D. was paid $1.6M of that.

Name
Kevin J. Knopp, Ph.D.President and Chief Executive Officer
Mark S. LevineChief Legal and Administrative Officer and SecretaryNot disclosed
Joseph H. Griffith IVChief Financial Officer and Treasurer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for 908 Devices. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board5

See all
  • E. Kevin HrusovskyChair · 12 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Keith L. CrandellDirector · 13 yr on the boardIndependentCompensation—Paid as an executive
  • Mark SpotoDirector · 13 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Michele M. LeonhartDirector · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Brandi C. Vann, Ph.D.Director · 0 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 28, 2025FY2024
Annual report10-KMar 7, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 8, 2024FY2023